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Abstract
Objectives: Sarcopenia and visceral obesity have been suggested to aggravate
each other, resulting in a vicious cycle. However, evidence based on prospective
study is very limited. Our purpose was to investigate whether visceral fat promotes
a decrease in skeletal muscle mass and vice versa.
Methods: We observed changes in anthropometric and body composition data
during a follow-up period of 27.6¡2.8 months in 379 Korean men and women
(mean age 51.9¡14.6 years) from the Korean Sarcopenic Obesity Study (KSOS).
Appendicular lean soft tissue (ALST) mass was calculated using dual-energy X-ray
absorptiometry, and visceral fat area (VFA) was measured using computed
tomography at baseline and follow-up examination.
Results: ALST mass significantly decreased, whereas trunk and total fat mass
increased in both men and women despite no significant change in weight and
body mass index. In particular, women with visceral obesity at baseline had a
greater decrease in ALST mass than those without visceral obesity (P50.001). In
multiple linear regression analysis, baseline VFA was an independent negative
predictor of the changes in ALST after adjusting for confounding factors including
age, gender, life style and body composition parameters, insulin resistance, high
sensitivity C-reactive protein and vitamin D levels (P50.001), whereas the
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association between baseline ALST mass and changes in VFA was not statistically
significant (P50.555).
Conclusions: This longitudinal study showed that visceral obesity was associated
with future loss of skeletal muscle mass in Korean adults. These results may
provide novel insight into sarcopenic obesity in an aging society.
Introduction
Aging is often accompanied by changes in body composition that lead to a shift
toward decreased muscle mass and increased fat mass, even in relatively weight-
stable, healthy individuals [1, 2]. Both obesity and sarcopenia, the age-related loss
of skeletal muscle mass and function, are important causes of frailty, disability,
morbidity, and mortality [3]. Diminished skeletal muscle and expanded visceral
fat may act synergistically, which may maximize their effects on physical
impairments and metabolic disorders [4].
Fat and muscle mass are known to be strongly interconnected from a
pathogenic point of view [4]. Previous studies suggested that sarcopenia may
aggravate obesity and vice versa. Loss of skeletal muscle induces a 2%–3% decline
in basal metabolic rate per decade after the age of 20 years, and a 4% decline per
decade after the age of 50 years [5]. In addition, sarcopenia reduces the intensity
and duration of physical activity, which results in decreased energy expenditure.
These changes may increase the risk of obesity and obesity-related metabolic
disorders, such as metabolic syndrome [3]. On the other hand, increased adiposity
induces chronic subclinical inflammation, which may contribute to the
development and progression of sarcopenia. Dysregulation of adipokines
originating from visceral adipose tissue, such as tumor necrosis factor-a (TNF-a),
interleukin-6 (IL-6), leptin, and adiponectin, has been reported to influence
insulin resistance and growth hormone (GH) secretion, which are closely
associated with sarcopenia [6]. Insulin is a pivotal anabolic signal and insulin
resistance is regarded to be the main factor that connects obesity and sarcopenia
[7].
Although these reports support the hypothesis that sarcopenia and obesity may
worsen each other, creating a vicious cycle, previous longitudinal human studies
that explore the contribution of visceral fat accumulation to changes in skeletal
muscle mass or vice versa are very limited. Furthermore, to the best of author’s
knowledge, there was no previous study to compare which one among sarcopenia
and visceral fat might be an initiating factor after adjusting potential confounding
factors.
Our aims in this prospective human study were therefore to examine changes in
parameters of obesity and sarcopenia using accurate standard imaging methods,
such as computed tomography (CT) and dual-energy X-ray absorptiometry
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(DXA), and to evaluate if baseline visceral fat area (VFA) are negatively associated
with changes in skeletal muscle mass and vice versa.
Research Design and Methods
Subjects and data collection
The Korean Sarcopenic Obesity Study (KSOS) is a longitudinal study funded by
the Korea Science and Engineering Foundation. This prospective observational
cohort study was designed to examine the prevalence of sarcopenia and sarcopenic
obesity in Korean adults with (diabetic KSOS cohort) or without diabetes (non-
diabetic KSOS cohort) and to evaluate effects of sarcopenia and sarcopenic obesity
on metabolic disorders and health outcomes [8, 9]. In this study, we analyzed
baseline and follow-up data from the KSOS. Eligible participants (20–86 years)
were those in the non-diabetic KSOS cohort; these subjects had no history of any
type of diabetes, cardiovascular disease (CVD) (myocardial infarction, unstable
angina, stroke or cardiovascular revascularization), stage 2 hypertension (resting
blood pressure, $160/100 mmHg), malignant disease, or severe renal or hepatic
disease. Participants underwent body compositional analysis using precise
techniques to measure muscle mass and visceral fat, namely DXA and CT,
simultaneously. Medical histories and lifestyle information were collected by
personal interview using a detailed questionnaire [10]. Physical activity was
classified into two categories: none or regularly. Regular exercise was defined as
exercising 30 minutes or more at least three times a week. Complete body
composition data were available for 379 participants at baseline and after a mean
follow-up of 27.6¡2.8 months. All participants provided written informed
consent, and the Korea University Institutional Review Board, in accordance with
the Declaration of Helsinki of the World Medical Association approved this study
protocol.
Anthropometric and body composition measurements
Height, body weight, and waist circumference were measured following
standardized procedures. Body mass index (BMI) was calculated as weight in
kilograms divided by the square of height in meters. A whole body DXA scan was
performed for each patient to measure both the total and regional components of
body composition using fan-beam technology (Hologic Discovery A, Hologic;
Bedford, MA, USA). Measurements of both arms, both legs, and the head were
separated from trunk measurements using computer-generated default lines with
manual adjustment in the anterior view planogram [11]. An experienced medical
radiology technician handled the adjustment of all subjects using specific
anatomical landmarks (chin, center of the glenohumeral joint, and femoral neck
axis). Total, trunk, and appendicular body composition were individually
evaluated. Appendicular lean soft tissue (ALST) mass (kg) was defined as the sum
of the lean soft tissue masses for the arms and legs, following the method of
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Heymsfield et al. [12]. Appendicular fat mass (AFM) was calculated as the sum of
fat mass from both arms and legs. Abdominal adipose tissue area was quantified
by CT (Brilliance 64, Philips Medical Systems, Cleveland, Ohio). Fat area was
determined by measuring the mean value of the pixels within the range of2190 to
230 Hounsfield units. Total abdominal fat area (TFA), VFA and subcutaneous fat
area (SFA) were measured using a 10-cm CT slice scan image between the fourth
and fifth lumbar vertebrae that was obtained during suspended respiration. VFA
was calculated by delineating the intra-abdominal cavity at the internal aspect of
the abdominal and oblique muscle walls surrounding the cavity and the posterior
aspect of the vertebral body. SFA was calculated by subtracting VFA from TFA.
Changes in each an anthropometric and body composition measurement between
baseline and follow-up were calculated as follow-up value minus baseline value.
Definitions of sarcopenia and visceral obesity
The predictive equation of Kim et al. [13] was applied to compute the total
skeletal muscle mass from ALST mass, using the following equation: [14]
Total skeletal muscle mass (kg)5(1.136ALST mass)2(0.026age) +
(0.616sex)+0.97 where sex50 for female and sex51 for men.
The skeletal muscle index (SMI (%); total skeletal muscle mass (kg)/weight (kg)
6100) was obtained by calculating the total skeletal muscle mass adjusted by
weight as described by Janssen et al. [15]. Sarcopenia was defined as an SMI of,2
SD below the sex-specific mean value for young reference group from the entire
study population [15]. The cutoff point for sarcopenia was 37.0% in men and
30.5% in women. Visceral obesity was defined as a visceral fat area exceeding
100 cm2 in both men and women [16].
Laboratory measurements
All blood samples were obtained in the morning after a 12-hour overnight fast and
were immediately stored at 280 C˚ for subsequent assays. Serum triglycerides and
high-density lipoprotein (HDL)-cholesterol levels were determined enzymatically
using a chemistry analyzer (Hitachi 747; Tokyo, Japan). A glucose oxidase method
was used to measure fasting plasma glucose (FPG), and high-sensitivity C-reactive
protein (hsCRP) levels were measured by Latex-enhanced Turbidometric
Immunoassay (HiSens hsCRP LTIA; HBI Co., Ltd.) with an interassay coefficient
of variation of 7.2%. Insulin resistance was calculated using Homeostasis Model
Assessment (HOMA) [17]. Serum 25[OH]D levels were measured using
radioimmunoassay kits (DIAsource Diagnostics, Nivelles, Belgium) with quality
control materials provided by the manufacturer.
Statistical analysis
Numerical data are expressed as means¡ standard deviations or medians [inter-
quartile ranges]. Categorical variables are presented as percentages. Baseline
Visceral Fat and Skeletal Muscle Mass
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anthropometric, body composition, and metabolic characteristics of participants
are presented separately for men and women. Differences in quantitative variables
between groups were investigated using the independent two-sample t-test or
Wilcoxon’s rank-sum test, and Pearson’s chi-squared test was used to test for
differences in the distribution of categorical variables. Paired-sample t-test or
Wilcoxon’s signed-rank test were performed to compare baseline and follow-up
levels of anthropometric and body composition parameters. Spearman correlation
analysis was performed to determine the relationships between VFA and changes
in ALST mass or vice versa. In addition, spearman’s partial correlation analysis
adjusting for age and gender was performed. Multiple linear regression analyses
using changes in VFA or ALST mass as the dependent variable were conducted to
determine the relative contributions made by each variable to the outcome
variables. Age, sex, smoking, alcohol, physical activity, systolic blood pressure
(SBP), diastolic blood pressure (DBP), total cholesterol, triglycerides, HDL-
cholesterol, fasting plasma glucose, hsCRP levels, 25[OH]D, BMI, AFM, ALST
mass, trunk fat mass, SFA, and VFA at baseline as well as changes in ALST mass,
VFA, and body weight were used as independent variables. Statistically significant
independent variables were chosen by means of the backward elimination
method. All statistical outcomes based on a two-sided test were obtained using
SAS for Windows (Version 9.2, SAS Institute Inc., Cary, NC, USA). We regarded a
P-value ,0.05 as statistically meaningful.
Results
Baseline clinical and metabolic characteristics of the study subjects are shown in
Table 1. No difference of total cholesterol, HOMA-IR, and hsCRP was found
between men and women. Age, SBP, DBP, triglyceride, and 25[OH]D were higher
in men than in women (P,0.001, respectively), whereas HDL cholesterol was
significantly lower in men than in women (Table 1). When men were compared
with women according to baseline anthropometric and body composition
indicators, BMI (P50.019), weight (P,0.001), VFA (P,0.001), ALST mass
(P,0.001), and total skeletal muscle mass (P,0.001) were all greater in men than
women. SFA and total fat mass were significantly greater in women (P,0.001,
respectively).
Anthropometric and body composition characteristics of the study participants
before and after the follow-up period are presented in Table 2. During that
timeframe, most men and women gained fat mass, whereas all body muscle
indices decreased significantly. Among the anthropometric and body composition
parameters, ALST mass, total skeletal muscle mass, and AFM decreased
significantly. On the contrary, trunk and total fat mass increased. However, there
were no changes in weight and BMI in either men or women. In addition, VFA
did not decrease in men, whereas it tended to be higher than baseline at the study
follow-up in women.
Visceral Fat and Skeletal Muscle Mass
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Results of correlation analysis between baseline VFA and changes in ALST mass,
and between baseline ALST mass and changes in VFA are presented in Fig. 1. VFA
at baseline was negatively associated with changes in ALST mass during follow-up
period (r520.20, P,0.001). Adjustment for age and sex did not affect the
strength of the association between baseline VFA and changes in ALST mass
(r520.17, P50.001). However, on the contrary, there were no relationships
between baseline ALST mass and changes in VFA (r520.08, P50.135).
Fig. 2 illustrates the changes in ALST mass or VFA in men and women
classified on the presence of visceral obesity or sarcopenia. Women with visceral
Table 1. Baseline clinical and metabolic characteristics of study subjects.
Men (n5141) Women (n5238) P-value
Age (years) 53.8¡13.9 50.8¡14.9 0.054
Systolic blood pressure (mmHg) 126.8¡12.6 120.5¡13.6 ,0.001
Diastolic blood pressure (mmHg) 83.5¡9.7 77.9¡10.2 ,0.001
Total cholesterol (mmol/L) 4.8¡0.9 4.8¡0.9 0.637
HDL cholesterol (mmol/L) 1.3¡0.3 1.5¡0.3 ,0.001
Triglycerides (mmol/L) 1.5 [1.0, 2.1] 1.1 [0.8, 1.6] ,0.001
Fasting plasma glucose (mmol/L) 5.1 [4.8, 5.5] 5.3 [5.0, 5.8] ,0.001
HOMA-IR 2.0 [1.4, 2.8] 1.9 [1.3, 2.7] 0.478
hsCRP (mg/L) 0.5 [0.2, 0.9] 0.4 [0.1, 0.9] 0.135
25[OH]D (nmol/L) 89.3 [65.4, 116.7] 63.3 [47.2, 91.3] ,0.001
Prevalence of visceral obesity (%) 81.6 47.1 ,0.001
Prevalence of sarcopenia (%) 4.6 5.6 0.694
HDL, high density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; hsCRP, high-sensitivity C-reactive protein; 25[OH]D, 25-
hydroxyvitamin D.
Data are presented as mean ¡ SD, median [inter-quartile range].
P-values were obtained from the independent two-sample t-test or Wilcoxon’s rank-sum test.
doi:10.1371/journal.pone.0115407.t001
Table 2. Body composition characteristics of study subjects at baseline and after 2 years.
Characteristics Men (n5141) Women (n5238)
Baseline Follow-up P-value Baseline Follow-up
P-
value
Body mass index (kg/m2) 24.9¡2.7 24.7¡2.7 0.182 24.1¡3.6 24.1¡3.8 0.661
Weight (kg) 72.1¡10.6 71.6¡11.2 0.123 59.2¡9.5 59.3¡9.8 0.619
Visceral fat area (cm2) 138.2 [107.7, 174.6] 138.3 [106.3, 178.1] 0.823 97.3 [60.9, 141.8] 99.9 [67.3, 141.3] 0.082
Appendicular fat mass (kg) 6.4 [5.5, 7.9] 6.0 [5.2, 7.3] ,0.001 10.0 [8.3, 12.2] 9.4 [7.7, 11.1] ,0.001
Trunk fat mass (kg) 6.4 [5.1, 8.2] 6.9 [5.1, 9.1] ,0.001 6.9 [5.2, 9.0] 8.0 [6.0, 10.6] ,0.001
Total fat mass (kg) 14.2 [12.0, 17.2] 14.3 [11.6, 17.6] 0.028 18.2 [15.0, 22.3] 18.3 [15.3, 22.6] 0.001
Appendicular lean soft tissue mass (kg) 26.2 [23.9, 29.1] 25.2 [22.9, 27.4] ,0.001 18.1 [16.8, 20.2] 17.4 [15.9, 18.9] ,0.001
Total skeletal muscle mass (kg) 30.2 [27.6, 33.5] 28.9 [26.3, 31.5] ,0.001 20.5 [19.0, 22.6] 19.6 [17.8, 21.3] ,0.001
Data are presented as mean ¡ SD, median [inter-quartile range].
P-values were obtained from paired-sample t-test or Wilcoxon’s signed-rank test.
doi:10.1371/journal.pone.0115407.t002
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obesity had more decreased ALST mass than those without visceral obesity (21.1
[21.8, 20.5] vs. 20.7 [21.4, 20.1], P50.001), whereas, in men, the difference
was not statistically significant (21.1 [22.0, 20.2] vs. 20.6 [21.8, 20.1],
P50.361). The difference of the changes in VFA based on the presence of
sarcopenia was not significant in both men and women.
Multiple regression analyses were performed using changes in VFA or ALST
mass as the dependent variable and clinical, metabolic, and body composition
parameters as independent variables (Table 3). Baseline VFA was independently
associated with changes in ALST mass (P50.001) after adjustment for
confounding parameters including age, gender, life style and body composition
parameters, insulin resistance, high sensitivity C-reactive protein and vitamin D
levels. On the other hand, the association between baseline ALST mass and
changes in VFA was not statistically significant (P50.555).
Discussion
Our study substantially supports the hypothesis of the contribution of increased
visceral fat to future loss of muscle mass. Additionally, for the first time, we
evaluated if baseline visceral fat area is negatively associated with changes in
Fig. 1. Relationship between baseline visceral fat area and changes in appendicular lean soft tissue mass and vice versa. Scatter plot of baseline
visceral fat area (cm2) against change in appendicular soft tissue mass (kg) (A) and vice versa (B).
doi:10.1371/journal.pone.0115407.g001
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Fig. 2. Changes in appendicular lean soft tissue mass in participants classified on the basis of visceral obesity (A) and changes in visceral fat
area according to the presence of sarcopenia (B) in men and women. The box plot display the 25th, median and 75th percentiles and the minimum and
maximum levels as horizontal lines outside the box.
doi:10.1371/journal.pone.0115407.g002
Table 3. Independent associations of changes in the appendicular lean soft tissue (ALST) mass and visceral fat area (VFA) and baseline clinical, metabolic
and body composition parameters during the 2-year follow-up period according to multiple linear regression analyses.
Dependent variable Independent variables Standardized b P-value
D ALST massa Baseline VFA 20.240 0.001
Baseline BMI 20.307 0.001
Alcohol drinking 20.091 0.066
DWeight 0.373 ,0.001
Baseline Subcutaneous fat area 20.401 ,0.001
Baseline trunk fat mass 0.655 ,0.001
DVFAb Smoking 20.131 0.040
Total cholesterol 20.104 0.035
DWeight 0.517 ,0.001
Baseline BMI 0.220 0.024
Baseline appendicular fat mass 20.312 ,0.001
Baseline trunk fat mass 20.177 0.048
Baseline ASM 20.036 0.555
Variables included in the model were age, sex, smoking, alcohol, physical activity, SBP, DBP, total cholesterol, triglycerides, HDL-cholesterol, fasting plasma
glucose, HOMA-IR, hsCRP levels, 25[OH]D, BMI, ALST mass, appendicular fat mass, trunk fat mass, subcutaneous fat area, and VFA at baseline as well as
change in ALST mass, VFA and weight.
aBaseline and changes in ALST mass among independent variables ware excluded in the model.
bBaseline and changes in VFA among independent variables ware excluded in the model.
Statistically significant variables were selected via the backward elimination method.
doi:10.1371/journal.pone.0115407.t003
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skeletal muscle mass and vice versa. We found that baseline visceral fat area
measured using CT influenced changes in ALST mass, although baseline ALST
mass did not predict changes in VFA during the follow-up period. This provides
an evidence that visceral obesity might be an influencing factor on skeletal muscle
mass. Furthermore, these results suggest that prevention of visceral obesity may
decrease the loss of skeletal muscle mass.
In this longitudinal study of apparently healthy Asian men and women with a
wide range of age, we found that total and trunk fat mass increased significantly in
both men and women, whereas appendicular muscle and appendicular fat mass
decreased without parallel changes in BMI and weight. These findings showed that
changes in body composition during aging were loss of muscle mass and
centralization of body fat. Recently, cross-sectional study showed that a new
anthropometric measure based on waist circumference (A Body Shape Index,
ABSI) was negatively associated with fat-free mass index, both in men and women
[18]. In addition, the lower-ABSI women and men showed a significant greater
fat-free mass index than the higher-ABSI groups [18]. Our longitudinal study
clearly demonstrated an independent and negative association between baseline
visceral fat and changes in skeletal muscle mass.
The rapid increase in numbers of older people in industrialized countries
imposes serious burden on health care system. Aging is associated with critical
changes in body composition and systemic metabolism. Peak skeletal muscle mass
is generally attained with the first three decades of life. Thereafter, there is a
progressive reduction in muscle mass of about 40% accompanied by a rise in fat
mass between the ages of 20 and 70 years [3]. Sarcopenia and obesity may act
synergistically to erode functional capacity and health status in elderly individuals
to a greater extent than either disorder alone [19]. Baumgartner et al. showed that
individuals with sarcopenic obesity at baseline were two to three times more likely
to report onset of disability during follow-up than lean sarcopenic or non-
sarcopenic obese subjects [20]. We observed in a previous study that visceral fat to
thigh muscle area (VMR), a single indicator of sarcopenic obesity, was
independently associated with metabolic syndrome [21]. Expanded fat mass may
exacerbate sarcopenia because chronic lipid accumulation has a deleterious effect
on the incorporation of amino acids and muscle protein synthesis [22].
Furthermore, chronic high fat feeding has been shown to impair the ability of
skeletal muscle to hypertrophy in response to increased mechanical load in mice
[23]. Pasco et al. reported that over a period of 5 years, an increase in body fat
mass has been accompanied by a decline in both lean mass and bone mass [24].
Koster et al. recently reported that greater total body fat mass measured using
DXA at baseline was associated with a greater decline in leg lean mass in both men
and women [25]. However, visceral obesity, which is known to be most closely
associated with metabolic deterioration and catabolic cytokines, was not
measured. Furthermore, they did not examine whether baseline muscle mass can
affect visceral fat. Interestingly, the present study first showed that baseline VFA
measured using CT influenced changes in ALST mass, although baseline ALST
mass did not predict changes in VFA during the follow-up period.
Visceral Fat and Skeletal Muscle Mass
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The etiology of sarcopenia is multi-factorial, and includes insulin resistance,
inflammation, oxidative stress, and hormonal changes [26]. Recent studies have
established that obesity is a state of low-grade, chronic inflammation that is
closely associated with insulin resistance [11]. Increased intramyocellular fat
content in obesity and aging interferes with the phosphorylation pathway of the
insulin receptor and GLUT-4 translocation [27]. Recent evidence suggests that
insulin resistance is associated with the development of sarcopenia through
alteration of mitochondrial function [28]. Furthermore, enlarged adipocytes and
activated macrophages in visceral adipose tissue produce pro-inflammatory
adipokines [29]. Schaap et al. reported that higher levels of inflammatory markers,
especially TNF-a and its soluble receptors, were associated with a greater 5-year
decline in thigh muscle area in the Health, Aging, and Body Composition study
[30]. IL-6 and CRP, known as ‘‘geriatric cytokines’’, increases during the aging
process, as does visceral obesity [3]. Haddad et al. reported that IL-6 infusion
resulted in atrophy of the tibialis anterior muscle in mice [31]. In the Longitudinal
Aging Study Amsterdam, higher levels of IL-6 and CRP were associated with a
greater decline in muscle strength over 3 years [32]. A 12-week combined
resistance and aerobic exercise program increased strength by an average of 38%
along with a significant reduction in CRP levels [33]. In our previous study
analyzing cross-sectional KSOS data, we found that hsCRP levels were negatively
correlated with SMI and positively correlated with VFA in both men and women
[34]. On the other hand, several studies have shown that vitamin D deficiency is
associated with various measures of obesity, including waist circumference [35],
and increases the risk of sarcopenia [36]. We recently observed that serum 25-
hydroxyvitamin D (25[OH]D) levels were independently associated with
sarcopenic obesity in Korean men [34]. Interestingly, the present study revealed
that baseline VFA were independently associated with changes in ALST mass even
after adjusting for the possible mediating factors, such as hsCRP, HOMA-IR and
25[OH]D levels during the follow-up period.
Intimate tissue cross-talk between adipose tissue and skeletal muscle may be
essential for the integrated control of systemic physiology in humans. Adipose
tissue-derived adipokines have been established as important regulators of insulin
resistance and metabolic homeostasis [29]. Carbo et al. reported that adminis-
tration of leptin, a prototype of adipokine, might decrease the rate of myofibrillar
protein synthesis in skeletal muscle without changes in circulating insulin levels
[37]. Attenuation of adiponectin contributes to the development of insulin
resistance and perpetuates chronic inflammation in muscle tissue [26]. Like
adipokines, recent studies found that skeletal muscle also secretes a variety of
biologically active factors, named ‘‘myokines’’. Bostrom et al. have shown that
PGC1-a overexpression in the muscles of mice stimulates an increase in
expression of FNDC5, a membrane protein that is cleaved and secreted as a novel
myokine, irisin [38]. Exercise increases circulating levels of irisin in mice and
humans. Furthermore, increased irisin levels turn on thermogenesis by inducing
the ‘‘browning’’ of white adipose tissue, thereby improving obesity and glucose
homeostasis [38]. These results support the concept that skeletal muscle may also
Visceral Fat and Skeletal Muscle Mass
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influence adipose tissue through circulating mediators such as myokines. Further
studies are required to explore the role of myokines in the interaction between
skeletal muscle and adipose tissue. Although, in this study, baseline skeletal
muscle mass did not predict the changes in VFA during the follow-up period,
longer follow-up period or larger number of participants may reveal baseline
ALST mass as an independent risk factor for the development of visceral obesity.
There are several limitations to this study. First, neither muscle strength nor
physical performance was considered when defining sarcopenia in the present
study. However, because obesity itself is known to affect muscle strength and
physical performance, a definition of sarcopenia based on those parameters may
act as confounding factors. Second, although the DXA has been applied as one of
the most commonly used clinical standards among several methods for studying
body composition [39], it has some limitations. DXA cannot evaluate the muscle
quality and composition in contrast with magnetic resonance image or CT [40–
42]. In addition, because an important assumption made by DXA is that the
hydration of fat-free mass is uniform, altered hydration status with aging may
result in an error in the each amount of lean and fat compartment [43, 44]. Third,
our cohort comprised well-functioning and generally healthy Asian men and
women, which limits ability to generalize our study results to other populations
with different ethnicity and characteristics. Finally, information on smoking
status, alcohol consumption, and physical activity was self-reported, which may
allow for a recall bias. On the other hand, strength of the current study is that it
employs a sample of Korean men and women with a wide range of age.
Furthermore, this longitudinal study was performed using well-defined inclusion
and exclusion criteria, which may allow excluding the confounding effects of
severe chronic diseases. In addition, we assessed skeletal muscle mass and visceral
fat area using precise imaging techniques to detect sarcopenia and visceral obesity,
such as DXA and CT, simultaneously at both baseline and follow-up examination.
In conclusion, this prospective cohort study demonstrated that increased
visceral fat may result in future loss of skeletal muscle mass, although decreased
skeletal muscle mass did not predict an increment of visceral fat in Korean men
and women. These results may provide novel insight into sarcopenic obesity in an
aging society.
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